|
审核状态: Project audit state: |
通过审核 Successful |
|
注册号: Registration number: |
ChiCTR2200062142 |
|
最近更新日期: Date of Last Refreshed on: |
2023-04-02 16:47:05 |
|
注册时间: Date of Registration: |
2022-07-25 00:00:00 |
|
注册号状态: |
预注册 |
|
Registration Status: |
Prospective registration |
|
注册题目: |
定量脑电图引导tDCS对Covid-19大流行期间负面情绪和恐惧消除的干预 |
|
Public title: |
Quantitative Electroencephalography-Guided tDCS Intervention in Negative Emotion and Fear Extinction during Covid-19 Pandemic |
|
注册题目简写: |
|
|
English Acronym: |
|
|
研究课题的正式科学名称: |
定量脑电图引导tDCS对Covid-19大流行期间负面情绪和恐惧消除的干预 |
|
Scientific title: |
Quantitative Electroencephalography-Guided tDCS Intervention in Negative Emotion and Fear Extinction during Covid-19 Pandemic |
|
研究课题代号(代码): Study subject ID: |
|
|
在二级注册机构或其它机构的注册号: The registration number of the Partner Registry or other register: |
|
申请注册联系人: |
Tania Alexandra Zhang- Couto |
研究负责人: |
Zhen Yuan |
|
Applicant: |
Tania Alexandra Zhang - Couto |
Study leader: |
Zhen Yuan |
|
申请注册联系人电话: Applicant telephone: |
+86 85256825792 |
研究负责人电话:
Study leader's |
+86 853 8822 4989 |
|
申请注册联系人传真 : Applicant Fax: |
研究负责人传真: Study leader's fax: |
||
|
申请注册联系人电子邮件: Applicant E-mail: |
yb87605@umac.mo |
研究负责人电子邮件: Study leader's E-mail: |
zhenyuan@umac.mo |
|
申请单位网址(自愿提供): Applicant website(voluntary supply): |
研究负责人网址(自愿提供): Study leader's website(voluntary supply): |
||
|
申请注册联系人通讯地址: |
16 Fo Chun Road, Solaria, Tower 10, 15 E, Tai Po district, Hong Kong SAR |
研究负责人通讯地址: |
E12-1047 / E12-1032/1036 FHS University of Macau |
|
Applicant address: |
Hong Kong |
Study leader's address: |
E12-1047 / E12-1032/1036 FHS University of Macau |
|
申请注册联系人邮政编码: Applicant postcode: |
研究负责人邮政编码: Study leader's postcode: |
||
|
申请人所在单位: |
University of Macau; Chinese University of Hong Kong |
||
|
Applicant's institution: |
University of Macau; Chinese University of Hong Kong |
||
|
研究负责人所在单位: |
Faculty of Health Sciences; University of Macau |
||
|
Affiliation of the Leader: |
Faculty of Health Sciences; University of Macau |
||
|
是否获伦理委员会批准: |
是 |
||
|
Approved by ethic committee: |
Yes |
||
|
伦理委员会批件文号: Approved No. of ethic committee: |
BSERE21-APP025-ICI |
伦理委员会批件附件: Approved file of Ethical Committee: |
查看附件View |
|
批准本研究的伦理委员会名称: |
研究委员会-研究伦理小组生物医学科学与工程研究伦理小组(人类参与者) |
||
|
Name of the ethic committee: |
RESEARCH COMMITTEE – PANEL ON RESEARCH ETHICS Sub-Panel on Biomedical Science & Engineering Research Ethics (Human Participants) |
||
|
伦理委员会批准日期: Date of approved by ethic committee: |
2022-05-23 00:00:00 | ||
|
伦理委员会联系人: |
Drina Wu |
||
|
Contact Name of the ethic committee: |
Drina Wu |
||
|
伦理委员会联系地址: |
澳门大学,澳门氹仔大学园N6 |
||
|
Contact Address of the ethic committee: |
Avenida da Universidade |
||
|
伦理委员会联系人电话: Contact phone of the ethic committee: |
+86 85388224989 |
伦理委员会联系人邮箱: Contact email of the ethic committee: |
zhenyuan@um.edu.mo |
|
研究实施负责(组长)单位: |
澳门科技发展基金 |
||||||||||||||||||||||||||||||||||||||||||||
|
Primary sponsor: |
Macao Science and Technology Development Fund |
||||||||||||||||||||||||||||||||||||||||||||
|
研究实施负责(组长)单位地址: |
恩里克亲王大道,编号43-53A, EDF。中国澳门特别行政区澳门广场,8楼C和11楼K |
||||||||||||||||||||||||||||||||||||||||||||
|
Primary sponsor's address: |
39 Shi-er-qiao Road, Chengdu, Sichuan |
||||||||||||||||||||||||||||||||||||||||||||
|
试验主办单位(项目批准或申办者): Secondary sponsor: |
|
||||||||||||||||||||||||||||||||||||||||||||
|
经费或物资来源: |
[FDCT 0020/2019/AMJ and FDCT 0011/2018/A1]; [MYRG 2020-00067-FHS, MYRG2019-00082- FHS and MYRG2018-00081-FHS]; |
||||||||||||||||||||||||||||||||||||||||||||
|
Source(s) of funding: |
[FDCT 0020/2019/AMJ and FDCT 0011/2018/A1]; [MYRG 2020-00067-FHS, MYRG2019-00082- FHS and MYRG2018-00081-FHS]; |
||||||||||||||||||||||||||||||||||||||||||||
|
研究疾病: |
Anxiety and Depression disorders |
||||||||||||||||||||||||||||||||||||||||||||
|
Target disease: |
Anxiety and Depression disorders |
||||||||||||||||||||||||||||||||||||||||||||
|
研究疾病代码: |
|
||||||||||||||||||||||||||||||||||||||||||||
|
Target disease code: |
|
||||||||||||||||||||||||||||||||||||||||||||
|
研究类型: |
干预性研究 |
||||||||||||||||||||||||||||||||||||||||||||
|
Study type: |
Interventional study |
||||||||||||||||||||||||||||||||||||||||||||
|
研究所处阶段: |
II期临床试验 | ||||||||||||||||||||||||||||||||||||||||||||
|
Study phase: |
2 |
||||||||||||||||||||||||||||||||||||||||||||
|
研究设计: |
非随机对照试验 |
||||||||||||||||||||||||||||||||||||||||||||
|
Study design: |
Non randomized control |
||||||||||||||||||||||||||||||||||||||||||||
|
研究目的: |
本研究旨在通过qEEG引导下的tDCS干预香港特别行政区COVID-19大流行期间焦虑抑郁共病恶化患者的治疗效果,特别是在闭眼和睁眼方案下,tDCS干预对qEEG谱功率活动和静息状态连接组织的影响。 |
||||||||||||||||||||||||||||||||||||||||||||
|
Objectives of Study: |
This study aims to use qEEG-guided tDCS to inspect the therapeutic effect of tDCS intervention on patients who suffer from anxiety-depression comorbidity deterioration amid the COVID-19 pandemic in HK SAR. In particular, the impact of tDCS intervention on qEEG spectral power activity and resting-state connectivity organization during eyes closed and eyes open protocols will be examined. |
||||||||||||||||||||||||||||||||||||||||||||
|
药物成份或治疗方案详述: |
患者组接受10次tDCS治疗每周一次持续10周。每周进行10次tDCS干预,包括消极情绪调节和恐惧消除两种方案。干预使用电池驱动的刺激器(Activadose, Caputron,美国),两个大约4 × 4厘米的橡胶电极,涂有电极导电凝胶和盐水。在第三次也是最后一次qEEG数据采集后,与每位参与者详细讨论结果。此外,我们还提供了一套认知行为治疗策略,结合第二代和第三代的方法来维持改善。实施同样的后续程序,对照组根据症状的严重程度进行调整;然而,只有临床组从qeeg引导的tDCS研究结束后开始接受每月随访。 |
||||||||||||||||||||||||||||||||||||||||||||
|
Description for medicine or protocol of treatment in detail: |
|
||||||||||||||||||||||||||||||||||||||||||||
|
纳入标准: |
男性或女性,年龄在20至45岁之间,有焦虑和抑郁症状,导致严重痛苦或功能障碍,右撇子(两名左撇子患者除外),英语熟练,视力正常或矫正至正常,无神经障碍史。所有参与者都是熟练的双语者(在英语国家生活和工作),并学习英语作为第二语言(L2)。 |
||||||||||||||||||||||||||||||||||||||||||||
|
Inclusion criteria |
Male or female between the age of 20 and 45 with a history of anxiety and depressive symptoms that cause significant distress or impairment in functioning, right-handed (except two left-handed patients), English proficient speakers, normal and corrected-to-normal vision, and no history of neurological disorders. All participants are proficient bilinguals (living and working in an English speaking country) and learned English as a second language (L2). |
||||||||||||||||||||||||||||||||||||||||||||
|
排除标准: |
排除标准包括使用药物、一般医疗状况以及可以用丧亲之痛更好地解释的症状。 |
||||||||||||||||||||||||||||||||||||||||||||
|
Exclusion criteria: |
The exclusion criteria include the presence of substance use, general medical conditions, and symptoms that are better explained by bereavement. |
||||||||||||||||||||||||||||||||||||||||||||
|
研究实施时间: Study execute time: |
从 From 2022-09-01 00:00:00至 To 2029-09-01 00:00:00 |
征募观察对象时间: Recruiting time: |
从 From 2022-09-01 00:00:00 至 To 2027-09-01 00:00:00 |
|
干预措施: Interventions: |
|
|
研究实施地点: Countries of recruitment and research settings: |
|
||||||||||||||||||||||||||||
|
测量指标: Outcomes: |
|
|
采集人体标本:
Collecting sample(s)
|
|
|
征募研究对象情况: Recruiting status: |
尚未开始 Not yet recruiting |
年龄范围: Participant age: |
|
||||||
|
性别: |
男女均可 |
Gender: |
Both |
||||||
|
随机方法(请说明由何人用什么方法产生随机序列): |
非随机对照试验 |
||||||||
|
Randomization Procedure (please state who generates the random number sequence and by what method): |
Non-Randomized controlled trial |
||||||||
|
是否公开试验完成后的统计结果: Calculated Results after the Study Completed public access: |
公开/Public |
|
盲法: |
|
|
Blinding: |
|
|
试验完成后的统计结果(上传文件): |
|
|
Calculated Results after
|
|
|
是否共享原始数据: IPD sharing |
否No |
|
共享原始数据的方式(说明:请填入公开原始数据日期和方式,如采用网络平台,需填该网络平台名称和网址): |
无 |
|
The way of sharing IPD”(include metadata and protocol, If use web-based public database, please provide the url): |
N/a |
|
数据采集和管理(说明:数据采集和管理由两部分组成,一为病例记录表(Case Record Form, CRF),二为电子采集和管理系统(Electronic Data Capture, EDC),如ResMan即为一种基于互联网的EDC: |
所有个人资料将严格保密。它们将单独存储在一个有密码保护的文件中,一旦不再需要,就会在五年内安全地处理掉。研究期间和研究结束后,共同研究者和主要研究者将是个人数据的保管人。在研究过程中,只有参与本项目的首席研究员和合作研究员才能为研究目的访问个人数据。 |
|
Data collection and Management (A standard data collection and management system include a CRF and an electronic data capture: |
All personal data will be kept strictly confidential. They will be stored separately in a password-protected file and will be securely disposed of as soon as it is no longer necessary and within five years. The co-investigator and principal investigator will be the custodian of the personal data during and after the study. During the study, only the chief investigator and co-investigator involved in the present project can access the personal data for research purposes only. |
|
数据与安全监察委员会: Data and Safety Monitoring Committee: |
有/Yes |